search
Back to results

To Assess the Efficacy of Over-the-counter Analgesics in the Prevention/Treatment of Transient Post-dose Symptoms Following Zoledronate Infusion in Post-menopausal Women

Primary Purpose

Osteopenia

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
zoledronic acid
Sponsored by
Novartis
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteopenia focused on measuring zoledronic acid, bisphosphonate, Low bone mass

Eligibility Criteria

45 Years - 75 Years (Adult, Older Adult)Female

Inclusion Criteria: Women greater than or equal to 45 years and less than or equal to 75 years of age inclusive Low bone mineral density Exclusion Criteria: Certain prior treatments for low bone mass/osteopenia Current use of medicines (prescription or non-prescription) for pain, fever, or inflammation Impaired kidney function Other protocol-defined inclusion/exclusion criteria may apply.

Sites / Locations

Outcomes

Primary Outcome Measures

Temperature increase

Secondary Outcome Measures

Questionnaires
VAS (visual analog scale)

Full Information

First Posted
September 1, 2005
Last Updated
April 26, 2012
Sponsor
Novartis
search

1. Study Identification

Unique Protocol Identification Number
NCT00145275
Brief Title
To Assess the Efficacy of Over-the-counter Analgesics in the Prevention/Treatment of Transient Post-dose Symptoms Following Zoledronate Infusion in Post-menopausal Women
Official Title
To Assess the Efficacy of Over-the-counter Analgesics in the Prevention/Treatment of Transient Post-dose Symptoms Following Zoledronate Infusion in Post-menopausal Women
Study Type
Interventional

2. Study Status

Record Verification Date
April 2012
Overall Recruitment Status
Completed
Study Start Date
December 2004 (undefined)
Primary Completion Date
October 2005 (Actual)
Study Completion Date
October 2005 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Novartis

4. Oversight

5. Study Description

Brief Summary
Zoledronic acid is a medicine being studied in people with low bone mass. Side effects such as headache, fever, muscle aches, and pains, may occur following the infusion. This study will investigate the use of over-the-counter medicines to improve these symptoms.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteopenia
Keywords
zoledronic acid, bisphosphonate, Low bone mass

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
455 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
zoledronic acid
Primary Outcome Measure Information:
Title
Temperature increase
Secondary Outcome Measure Information:
Title
Questionnaires
Title
VAS (visual analog scale)

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
45 Years
Maximum Age & Unit of Time
75 Years
Eligibility Criteria
Inclusion Criteria: Women greater than or equal to 45 years and less than or equal to 75 years of age inclusive Low bone mineral density Exclusion Criteria: Certain prior treatments for low bone mass/osteopenia Current use of medicines (prescription or non-prescription) for pain, fever, or inflammation Impaired kidney function Other protocol-defined inclusion/exclusion criteria may apply.
Facility Information:
City
Unavailable
State/Province
Georgia
Country
United States
City
Unavailable
State/Province
Illinois
Country
United States
City
Unavailable
State/Province
Indiana
Country
United States
City
Unavailable
State/Province
Iowa
Country
United States
City
Unavailable
State/Province
Kansas
Country
United States
City
Unavailable
State/Province
Washington
Country
United States
City
Multiple
Country
Australia
City
Multiple
Country
Canada
City
Multiple
Country
Russian Federation
City
Multiple
Country
South Africa

12. IPD Sharing Statement

Learn more about this trial

To Assess the Efficacy of Over-the-counter Analgesics in the Prevention/Treatment of Transient Post-dose Symptoms Following Zoledronate Infusion in Post-menopausal Women

We'll reach out to this number within 24 hrs